Form 4: ORIC CFO Exercises Options, Sells Shares in Planned Trade

Oric Pharmaceuticals' CFO, Dominic Piscitelli, exercised stock options and subsequently sold 52,000 shares of common stock for a significant gain.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), engaged in a series of transactions on February 24, 2026.
• Piscitelli exercised stock options to acquire 52,000 shares of common stock at an exercise price of $4.36 per share.
• Immediately following the option exercise, he sold 52,000 shares of common stock at a weighted average price of $13.5132 per share.
• The sale price ranged from $13.50 to $13.53 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Piscitelli on June 24, 2025.
• Following these transactions, Mr. Piscitelli directly beneficially owns 68,148 shares of common stock and 144,500 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While insider selling can sometimes be a concern, the pre-planned nature via a 10b5-1 plan and the significant gain realized by the CFO suggest a routine compensation event rather than a negative signal about the company's prospects.

Positives

• The Chief Financial Officer realized a significant gain from the exercise of options and subsequent sale of shares, indicating personal financial benefit.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned and routine compensation event rather than a reaction to new, non-public information.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be interpreted by some investors as a lack of confidence in the company's near-term stock price appreciation, although this is a common practice for executive compensation and liquidity.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving option exercises and subsequent sales, are common occurrences in the biotechnology and pharmaceutical sectors. Executives often use pre-arranged 10b5-1 plans to manage their equity compensation, providing liquidity and diversification while adhering to insider trading regulations. This transaction by Oric's CFO is consistent with typical executive compensation practices in the industry.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO could be viewed neutrally as a routine compensation event or slightly negatively if interpreted as a lack of confidence, though the 10b5-1 plan mitigates this. The transaction itself does not directly impact the company's operations or financial health.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Dominic Piscitelli, CFO, Insider Trading, Stock Options, Share Sale, Rule 10b5-1 Plan, Executive Compensation, SEC Form 4